Anti-H1N1v Vaccine — Competitive Intelligence Brief

Anti-H1N1v Vaccine (Anti-H1N1v Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated influenza vaccine H1N1 influenza virus hemagglutinin and neuraminidase antigens Immunology / Infectious Disease Biologic

Target snapshot

Anti-H1N1v Vaccine (Anti-H1N1v Vaccine) — Institut National de la Santé Et de la Recherche Médicale, France. This vaccine stimulates the immune system to produce antibodies and cellular immunity against the H1N1 influenza virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-H1N1v Vaccine TARGET	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
SD Fluzone Vaccine	SD Fluzone Vaccine	Insight Therapeutics, LLC	marketed	inactivated influenza vaccine
ccIIV4	ccIIV4	Vanderbilt University Medical Center	marketed	Inactivated influenza vaccine
Seasonal trivalent influenza vaccine, Anflu®	Seasonal trivalent influenza vaccine, Anflu®	Center for Disease Prevention and Control of Beijing Military Region	marketed	inactivated influenza vaccine
Vaxigrip Tetra Sanofi Pasteur Europe	Vaxigrip Tetra Sanofi Pasteur Europe	Aarhus University Hospital	marketed	Inactivated influenza vaccine (quadrivalent)
SD-QIV	SD-QIV	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Seqirus · 5 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
4. Green Cross Corporation · 4 drugs in this class
5. Novartis · 2 drugs in this class
6. SK Chemicals Co., Ltd. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Hospital Israelita Albert Einstein · 2 drugs in this class
9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class